Archive - September 2024
Cell and Gene Therapy Production Facilities
PCI Pharma Invests More Than $365 Million in New and Existing Facilities in US and EU
Forging Ahead with Continuous Manufacturing for mRNA (BIO 2024)
Bormioli Pharma Display at CPHI Milan to Include Low-Impact, Pharma-Grade Product Range
Oral Lipid-Based Formulations: Unlocking Value in Early-Stage Pharmaceutical Development
Prioritizing Formulation Strategies for Temperature-Sensitive Biotherapeutics
Cryoport and SK pharmteco Partner on Cell and Gene Therapies
EMA Suspends Sickle Cell Disease Medicine